Claremont, CA (PRWEB) September 30, 2014
Each year in the US, more than 1 million burn injuries require medical attention. In the military, burn injury is a ubiquitous threat and brings serious complications to battlefield medical care. More than 800 service members sustained burn injuries in Iraq and Afghanistan. Burn wounds heal slowly, remain inflamed and often become infected, producing scars that can be excessive, physically debilitating and functionally damaging. While developments in supportive care have improved the survivability of these wounds, scientists are still seeking innovations to increase healthy tissue regeneration. Synedgen’s new burn treatment has been shown to improve the rate of wound healing and to reduce scar formation in 3rd degree burns.
Because of these successful results in a Phase I contract, Synedgen has received follow-up funding in a highly competitive Phase II Small Business Innovation Research (SBIR) from the US Army Medical Research and Materiel Command. In the Phase I studies, Synedgen’s topical polysaccharide treatment reduced inflammation and stimulated enhanced healing with the reduction of scarring in 3rd degree models of burn injury. Analyses of the wounded tissues and their cellular responses showed that the Synedgen product reduces the magnitude and duration of the inflammatory phase, which in turn stimulates the wound closure and initiates the regenerative phase to heal faster and without the scarring typical of these injuries.
“The studies that led to our current Phase II effort supported our hypotheses regarding the regenerative effect of our wound product with clear evidence of reduced scar formation,” stated Synedgen president Dr. Shenda Baker. “This new funding will allow us to validate the manufacture of the product, to optimize the activity through determination of optimal dosage and duration, and to plan our next steps into human clinical trials. Our goal is to help burn patients recover more quickly and with fewer debilitating scars.”
Dr. William Wiesmann, Synedgen CEO, noted that while burns historically are involved in only 5-20% of military trauma, they tend to be severe and are very difficult to treat. Once the scarring process starts it is almost impossible to reverse it. “We hope our new treatment will not only reduce these damaging scars but result in improved function of burned tissues with restoration of the tissue to a more normal state.”
The previous work has supported by the US Army Medical Research and Materiel Command under Contract No. W81XWH-13-C-0053. The views, opinions and/or findings contained in this release are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Synedgen Inc. is an innovative pharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. Product development is targeted to specifically address unmet needs for therapies to treat inflammation, damage or infection at dermal, pulmonary and gastrointestinal surfaces.
Synedgen’s Corporate Headquarters, Research Laboratories and Manufacturing Facility are in Claremont CA. Additional information can be found at Synedgen’s web site at http://www.synedgen.com.